Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL) AMERICAN JOURNAL OF HEMATOLOGY Tandon, N., Sidana, S., Dispenzieri, A., Gertz, M. A., Lacy, M. Q., Dingli, D., Buadi, F. K., Fonder, A. L., Hayman, S. R., Hwa, Y., Hobbs, M. A., Kapoor, P., Gonsalves, W. I., Leung, N., Go, R. S., Lust, J. A., Russell, S. J., Kyle, R. A., Rajkumar, S., Kumar, S. K. 2018; 93 (1): 17–22

Abstract

Achievement of a normal FLC ratio (FLCr) following treatment indicates hematologic response and suggests better outcomes in light chain amyloidosis (AL). We examined if elevated involved free light chain (hiFLC) impacts outcomes in patients achieving normal FLCr. We retrospectively analyzed 345 AL patients who were diagnosed within a 10-year period (2006-2015) and had 2 consecutive normal FLCr values after 1st line treatment. Among these, patients with hiFLC at 1st reading of normal FLCr (hiFLC1; n?=?166; 48.1%) were compared to those who did not (n?=?179; 51.9%). Patients with AL who have hiFLC1 after initial therapy had higher rates of multi-organ involvement (63.3 vs 46.4%; P?=?.002) and patients in advanced Mayo stage (42.9 vs 32.2%; P?=?.04) at diagnosis. The median progression free survival [PFS; 38.2 (95%CI; 26.4, 55.4) vs 67.1 (95%CI; 55.8, 88) months; P?=?.0002] and overall survival [OS; 94.4 (95%CI; 78, 107.1) vs not reached (NR, 95%CI; 116.1, NR) months; P?

View details for DOI 10.1002/ajh.24919

View details for Web of Science ID 000417527300011

View details for PubMedID 28960427